-
公开(公告)号:US20250064792A1
公开(公告)日:2025-02-27
申请号:US18822966
申请日:2024-09-03
Inventor: Addolorata PISCONTI
IPC: A61K31/444 , A61K31/00 , A61K31/222 , A61K31/26 , A61K31/505 , A61K38/00 , A61K45/06 , A61P21/00 , A61P25/14
Abstract: The invention provides anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopa-thy, as well as a method for promoting muscle regeneration in a subject with a myopathy, the method comprising providing the subject with a therapeutically effective amount of an elastase inhibitor. Further provided is a pharmaceutical composition comprising anelastase inhibitor for use in the promotion of muscle regeneration in the treatment of a myopathy. Elastase inhibitors may have a protective effect on muscle progenitor cells and their regenerative potential, which aids muscle cell regeneration. By protecting regenerative potential of muscle progenitor cells, elastase inhibitors enable or enhance the grown of new or existing muscle fibres.
-
公开(公告)号:US20250064757A1
公开(公告)日:2025-02-27
申请号:US18629894
申请日:2024-04-08
Applicant: Duke University
Inventor: Kaitlyn ANDREANO , Ching-yi CHANG , Donald P. MCDONNELL , Stephanie L. GAILLARD
IPC: A61K31/138 , A61K9/00 , A61K9/70 , A61K31/00 , A61K31/192 , A61K31/40 , A61K45/06 , A61P5/00 , A61P35/00 , A61P35/04 , C12Q1/6827 , C12Q1/6886
Abstract: The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
-
3.
公开(公告)号:US20250058092A1
公开(公告)日:2025-02-20
申请号:US18935304
申请日:2024-11-01
Applicant: Caliber Therapeutics, LLC
Inventor: William R. Baumbach , Darren R. Sherman , Robert S. Burgermeister
Abstract: Devices and methods for balloon delivery of rapamycin and other hydrophobic compounds to the wall of blood vessels. Balloon catheters, such as those used for stent deployment, are modified with the addition of a reservoir of dry micelles. The micelle preparation is reconstituted and the micelles are mobilized when the aqueous solution used to inflate the balloons is injected into the catheter. The micelles are infused into tissue surrounding the balloon when pressurized fluid within the balloon leaks through the wall of the balloon.
-
4.
公开(公告)号:US20250049744A1
公开(公告)日:2025-02-13
申请号:US18931828
申请日:2024-10-30
Inventor: Sadasivan VIDYASAGAR , Stephen J. GATTO , Daniel B. DENNISON
IPC: A61K31/198 , A61K31/00 , A61K31/197 , A61K31/405 , A61P1/00 , A61P1/12 , A61P3/12 , A61P29/00 , A61P31/12 , A61P31/18 , A61P35/00
Abstract: The subject invention provides therapeutic compositions and uses thereof for the treatment or amelioration of symptoms of a disease selected from the group consisting of: Ebola virus infection, HIV infection, ataxia, environmental enteropathy, cancer, hangover, inflammatory disease, and porcine epidemic diarrhea. In preferred embodiments, the composition includes a combination of one or more amino acids selected from the group comprising lysine, aspartic acid, glycine, isoleucine, threonine, tyrosine, valine, tryptophan, asparagine and/or serine.
-
公开(公告)号:US20250032517A1
公开(公告)日:2025-01-30
申请号:US18417252
申请日:2024-01-19
Applicant: POVIVA CORP
Inventor: John Docherty , Christopher Andrew Bunka
Abstract: Disclosed herein are compositions and methods for delivering compositions to a subject in need of treatment for epilepsy. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering cannabidiol and CBD-containing compositions to subjects in need of treatment for epilepsy.
-
公开(公告)号:US20250031728A1
公开(公告)日:2025-01-30
申请号:US18918297
申请日:2024-10-17
Applicant: LES PRODUITS VETWATER INC.
Inventor: Pierre Luc Gingras
Abstract: The present disclosure relates to a liquid drinking formulation for consumption by pets, particularly cats, for preventing and/or treating urinary disorders, and stimulating water consumption. The drinking formulation comprises water that has less than 200 ppm of total minerals, and a pH between 5.9 and 7.0. Further described is a method for treating and/or preventing a urinary disorder, stimulating water consumption, and/or maintaining urinary health, in a pet, said method comprising administering the drinking formulation described herein to said pet.
-
7.
公开(公告)号:US12209285B2
公开(公告)日:2025-01-28
申请号:US17232795
申请日:2021-04-16
Applicant: BPGbio, Inc.
Inventor: Niven Rajin Narain , John Patrick McCook
IPC: C12Q1/6886 , A61K31/00 , A61K31/122 , C12Q1/6883 , G01N33/573 , G01N33/574
Abstract: Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.
-
公开(公告)号:US12201604B2
公开(公告)日:2025-01-21
申请号:US18416748
申请日:2024-01-18
Applicant: Vanda Pharmaceuticals Inc.
IPC: A61K31/343 , A61K9/00 , A61K31/00 , A61K31/05 , A61K31/15 , A61K31/277 , A61K31/496 , A61K45/06 , A61P25/20 , G01N30/72 , G01N33/68 , G01N33/74 , G16H50/20
Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
-
公开(公告)号:US20250009767A1
公开(公告)日:2025-01-09
申请号:US18765566
申请日:2024-07-08
Applicant: Fertin Pharma A/S
Inventor: Helle Wittorff , Sanne Skov Jensen , Gitte Nykjær Nikolajsen , Gordon Findlay Dawson
Abstract: An adhesive oral disc for sustained release of cannabinoids is presented. The disc includes one or more cannabinoids and is composed of at least a mucosal contacting layer having a mucosal contacting surface operable to be fixed to the gingiva of a person in need of alleviation or treatment of a medical condition, where the mucosal contacting layer includes one or more mucoadhesive polymers allowing the adhesive oral disc to adhere to the gingiva for an extended period of time. Further, the disc includes a non-mucoadhesive module fused to the mucosal contacting layer, where the non-mucoadhesive module includes a solid tablet composition allowing the non-mucoadhesive module to dissolve within an extended period of time upon adhesion of the adhesive oral disc to the gingiva. The invention is particularly useful for alleviation or treatment of ulcers.
-
公开(公告)号:US20250009752A1
公开(公告)日:2025-01-09
申请号:US18891542
申请日:2024-09-20
Applicant: Supernus Pharmaceuticals, Inc.
Inventor: Christopher D. BREDER
IPC: A61K31/5375 , A61K31/00
Abstract: The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.
-
-
-
-
-
-
-
-
-